PFIZER INC
PFENYSETrading Snapshot
- Day Range
- $28.12 β $28.54
- 52-Week Range
- $23.58 β $29.21
- Volume
- $4.59B
- Avg Volume
- $5.16B
- Shares Outstanding
- 5.70B
- Next Earnings
- Nov 7, 2026
Fundamentals Snapshot
- Annual Revenue
- $62.58B
- Last Q Revenue
- $15.03B
- P/E Ratio
- 37.7
- P/S Ratio
- 2.6x
- EPS (TTM)
- $0.76
- Dividend Yield
- 5.99%
- Dilution (1yr)
- β0.3%
Why Investors Own PFE
- βHigh-growth profile β revenue up +45.2% YoY with expanding US Equity exposure.
- βHealthy economics β 28% gross margin and 24% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
PFIZER INC
PFEAbout PFIZER INC
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Price Target
βLatest News & Updates
Novo vs. Pfizer: Which Large Drugmaker Offers Better Growth Prospects?
NVO and PFE offer different growth paths, with diversified portfolios, pipelines and near-term challenges shaping their outlooks.

Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer
BRISBANE, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein deg

Pfizer: Growth Portfolio And Cost Cuts Support A Buy Through The LOE Trough
Pfizer is rated a Buy, with a compelling risk-reward profile despite near-term COVID normalization and patent expiry headwinds. PFE's new and acquired products are delivering strong double-digit growth, helping offset lo
Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Pfizer Advances Today's Cancer Care and Tomorrow's Potential Breakthroughs at ESMO
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) will present data from 45 company-sponsored, investigator-sponsored, and collaborative research abstracts at the European Society for Medical Oncology (ESMO) Congress, t

Buy 5 Barron's Better Bets (Than T-Bills) Out Of 11 'Safer' September DiviDogs
Long-term bond yields persist despite pressure and circular remedies. But investors looking for income can still find plenty of attractive opportunities with dividend-paying stocks that have healthy yields. β23 stocks pa